Passion for People Development

Selmod is raising CHF 6–8 million to advance our antibacterial preclinical candidate through lead optimization into IND-enabling studies, and to finalize the lead optimization of our antifungal platform.

Our Lean Business Model

Selmod operates a capital-efficient, semi-virtual structure. By strategically outsourcing development to qualified, certified Contract Research Organizations (CROs), we:

.........• Minimize CAPEX by avoiding the cost of extensive in-house infrastructure
.........• Maximize Efficiency by directing investor capital toward high-value R&D milestones and IP development
.........• Ensure Scalability by maintaing operational flexibility to adapt quickly to scientific and market demands.

A Supportive Regulatory Landscape

The market for Antimicrobial Resistance (AMR) therapeutics is increasingly favorable. Regulatory incentives such as the U.S. GAIN Act, QIDP designation, Fast Track eligibility, and Priority Review can offer:

.........• Accelerated development pathways.
.........• Extended market exclusivity.
.........• Enhanced asset value through expedited reviews.
.........• Potential value creation via Priority Review Vouchers.

Potential future reimbursement upside

The proposed PASTEUR Act, which has not yet been enacted by the U.S. Congress, reflects growing political recognition of AMR as a critical healthcare priority. Its proposed subscription-based reimbursement model could:

.........• Unlock significant revenue potential beyond traditional licensing.
.........• Improve commercial predictability for antibiotic developers.
.........• Create additional value-realization opportunities for innovative anti-infective therapies.